Af­ter paint­ing a poor safe­ty pro­file, Pfiz­er and Eli Lil­ly are shoot­ing for a new pain drug OK any­way

Months af­ter an­a­lysts wrote off the NGF pain drug tanezum­ab as a per­pet­u­al los­er, Pfiz­er and Eli Lil­ly have de­cid­ed to push ahead and see if they can’t squeeze past the FDA with the low-dose ver­sion of this ther­a­py.

Pfiz­er post­ed the news with their Q2 up­date on Mon­day, not­ing that they de­cid­ed to go for it on the 2.5 mg dose af­ter a sit-down with reg­u­la­tors and a care­ful re­view of the “to­tal­i­ty” of the da­ta. The 5 mg dose is be­ing shelved.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER